[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"continuous-renal-replacement-therapy-crrt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:continuous-renal-replacement-therapy-crrt":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,75,98,133,159,184,211,238,262],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100632793","phase-4-nafamostat-mesylate-versus-regional-citrate-anticoagulation-for-continuous-renal-replacement-therapy-in-sepsis-associated-acute-kidney-injury-100632793",false,"NCT07518303","Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury","NICE-AKI","Inclusion Criteria:\n\n* Age 18 to 90 years, inclusive, regardless of sex.\n* Meets Sepsis 3.0 diagnostic criteria and develops acute kidney injury within 7 days after the diagnosis of sepsis.\n* After adequate resuscitation, meets KDIGO 2012 stage 2 or stage 3 acute kidney injury criteria, including any of the following:\n\nSerum creatinine increased to more than 3 times baseline; or Serum creatinine ≥4.0 mg\u002FdL \\[353.6 μmol\u002FL\\]; or Urine output \\\u003C0.3 mL\u002Fkg\u002Fh for ≥24 hours; or Anuria, defined as extremely low or absent urine output, lasting ≥12 hours.\n\nOr has an indication for CRRT, including any of the following:\n\nBlood urea nitrogen \\>150 mg\u002FdL; or Serum potassium \\>6 mmol\u002FL; or pH \\\u003C7.15; or Organ edema and\u002For fluid overload in the setting of AKI that is refractory to diuretic therapy.\n\n* Expected duration of CRRT treatment \\>48 hours.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Requirement for therapeutic anticoagulation, such as pulmonary embolism or deep vein thrombosis.\n* Contraindication to systemic anticoagulation.\n* Hemolytic uremic syndrome or thrombotic thrombocytopenic purpura.\n* Acute liver failure and\u002For shock with persistent severe lactic acidosis, defined as two consecutive measurements of pH \\\u003C7.2 lasting for more than 2 hours, with lactate \\>72.1 mg\u002FdL \\[8 mmol\u002FL\\].\n* Chronic kidney disease requiring long-term regular dialysis.\n* Acute kidney injury caused by permanent bilateral renal artery occlusion or surgical injury.\n* Acute kidney injury caused by glomerulonephritis, interstitial nephritis, or vasculitis.\n* Known allergy to study drugs, including nafamostat mesylate, sodium citrate, or their excipients.\n* Kidney transplantation within 1 year.\n* Planning pregnancy in the near term, pregnancy, or lactation.\n* HIV infection.\n* Only adsorptive filters such as oXiris are available at study enrollment.\n* Participation in another clinical trial within the previous 3 months.\n* Judged by the investigator to be in a moribund state or unlikely to complete the study intervention and primary outcome assessment, including but not limited to expected death within 24 hours after enrollment, decision for do-not-resuscitate order or limitation\u002Fwithdrawal of life-sustaining treatment, or planned abandonment of active treatment and self-discharge within 24 hours due to terminal disease or patient\u002Ffamily preference.\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for enrollment.","ALL","18 Years","90 Years",{"count":20,"type":21},1162,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This multicenter, randomized, open-label, active-controlled, parallel-group trial will evaluate the efficacy and safety of nafamostat mesylate anticoagulation compared with regional citrate anticoagulation in adult patients with sepsis-associated acute kidney injury requiring continuous renal replacement therapy. Eligible participants will be randomized in a 1:1 ratio to receive either nafamostat mesylate or regional citrate anticoagulation during CRRT. The primary outcome is MAKE30, a composite of all-cause mortality, new or ongoing renal replacement therapy, or persistent renal dysfunction within 30 days after randomization. Secondary outcomes include filter lifespan, CRRT-free days, 30-day all-cause mortality, renal replacement therapy status, persistent renal dysfunction, ICU and hospital mortality, length of stay, CRRT duration, major bleeding, new bloodstream infection during ICU stay, SOFA score, number of filters used, and protocol-defined safety outcomes.",[27,28,29],"Sepsis","Acute Kidney Injury","Continuous Renal Replacement Therapy (CRRT)",[31,29,27,32,33],"Nafamostat Mesylate","Acute Kidney Injury (AKI)","Randomized Clinical Trial (RCT)","NOT_YET_RECRUITING","2026-06-01",{"date":37,"type":38},"2026-06-03","ACTUAL",{"date":40,"type":21},"2026-06-10",{"date":42,"type":21},"2028-12-10",{"name":44,"class":45},"Jianfeng Xie","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100621014","insights-into-the-continuous-renal-replacement-therapy-to-critical-ill-patients-100621014","NCT07365111","Insights Into the Continuous Renal Replacement Therapy to Critical Ill Patients","Insights Into the Characteristics, Prescription and Delivery of Continuous Renal Replacement Therapy to Critical Ill Patients - The iCRRT Data Registry","iCRRT","Inclusion Criteria:\n\n1. Admission to an intensive care unit\n2. CRRT therapy\n\nExclusion Criteria:\n\n1. End-stage kidney disease\n2. CRRT \\\u003C24 hours",{"count":55,"type":21},100000,"90 Days","OBSERVATIONAL","This is a multinational, prospective, observational study designed to characterize patient demographics, prescription parameters, and process measures of continuous renal replacement therapy (CRRT) in intensive care units (ICUs) worldwide. The study aims to examine similarities and differences in CRRT practices and outcomes among critically ill adult patients across a global network of medical centers.\n\nThe goal is to develop a large, comprehensive repository of data on CRRT practices and outcomes. This repository will enable characterization of variation in standard CRRT practices across medical centers. Natural variability in practice patterns-both between and within centers-will provide an opportunity to compare outcomes associated with different approaches and to generate high-quality preliminary data to inform future interventional trials.\n\nPrimary Objective\n\n\\- To describe global patient characteristics, CRRT modalities, and clinical outcomes among patients receiving CRRT.\n\nSecondary Objectives\n\n* To compare clinical outcomes across geographic regions and CRRT modalities.\n* To identify patient-level and practice-level predictors of outcomes.\n* To assess the impact of comorbid conditions (e.g., diabetes mellitus) on CRRT outcomes.\n\nExploratory Objectives\n\n* To evaluate long-term renal outcomes and patient-reported quality of life.\n* To explore health economics and resource utilization related to CRRT.\n\nStudy Population All patients receiving CRRT as part of routine clinical care in the ICU at participating centers will be eligible for inclusion.\n\nData Collection The study will support an epidemiological assessment of patients undergoing CRRT, including, but not limited to, demographics, underlying disease states, severity of illness, physiological support, indications for CRRT, and clinical outcomes. Outcomes of interest include ICU and hospital mortality, ICU and hospital length of stay, and renal recovery.",[29,28,60,61],"Renal Dialysis","Critical Illness",[63,64,28,65],"Continue Renal Replacement Therapy","Dialysis","Intensive Care Unit","2026-05-28",{"date":35,"type":38},{"date":69,"type":21},"2026-07-01",{"date":71,"type":21},"2036-12-31",{"name":73,"class":45},"University of Alberta",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":74},"100638798","effect-of-high-versus-standard-protein-intake-in-critically-ill-patients-with-acute-kidney-injury-requiring-continuous-renal-replacement-therapy-100638798","NCT07596043","Effect of High Versus Standard Protein Intake in Critically Ill Patients With Acute Kidney Injury Requiring Continuous Renal Replacement Therapy","Effect of High Versus Standard Protein Intake in Critically Ill Patients With Acute Kidney Injury Requiring Continuous Renal Replacement Therapy: A Randomized Controlled Trial (PROTEIN-CRRT)","PROTEIN-CRRT","Inclusion Criteria:\n\n* Adult (≥18 years old)\n* AKI receiving CRRT within 7 days after ICU admission\n* Achieve and tolerate calories 70% of target daily caloric requirement (20 kcal \u002Fkg\u002Fd) within 7 days after ICU admission by enteral feeding\n* Participant or their surrogates is willing and able to give informed consent for participation in the study\n\nExclusion Criteria:\n\n* Moribund or withholding of treatment\n* Kidney transplant recipient\n* Previously diagnosed end-stage kidney disease (ESKD) currently on kidney replacement therapy\n* Pregnancy or breastfeeding\n* Hepatic encephalopathy (West Haven grade 3-4)\n* Burn patients\n* Patients whom the responsible clinician felt that the patient either needed low or high protein\n* Severe complications of diabetes such as ketoacidosis, hyperosmolar coma\n* Had pre-existing neuromuscular disorders\n* Previously leg amputations",{"count":84,"type":21},56,[86],"NA","During critical illness, patients experience a hypercatabolic state. This hypercatabolic state causes muscle wasting in patients, resulting in intensive care unit acquired weakness (ICU-AW). ICU-AW is associated with prolonged mechanical ventilation (MV) weaning, extubating failure and extended length of stay. Previously recognized risk factors for ICU-AW include shock, sepsis, multiple organ failure, hyperglycemia, and prolonged exposure to corticosteroids, sedatives, or paralytic agents.\n\nCritical illness is complicated by the development of acute kidney injury (AKI). AKI causes muscle wasting by increasing protein degradation and decreasing protein synthesis. Furthermore, patients with severe AKI often require renal replacement therapy (RRT), which contributes to additional protein loss. Studies have estimated that amino acid losses associated with RRT may range from 5 to 19 g\u002Fd, with greater losses observed in patients undergoing continuous renal replacement therapy (CRRT). AKI requiring CRRT has recently been proposed to contribute to an increased risk of ICU-AW.\n\nTherefore, critically ill patients with AKI may require increased protein intake to compensate for these metabolic alterations. However, higher protein intake, particularly during the early acute phase of critical illness, may be associated with prolonged need for RRT or delayed kidney recovery.\n\nThe objective of this trial is to compare the effects of a high protein intake versus a standard protein intake on muscle mass change in critically ill patients with AKI requiring CRRT.\n\nThe goal of this clinical trial is to learn if high protein intake (1.5-1.7 g\u002Fkg\u002Fd) can reduce ICU associated weakness in critically ill patients with AKI requiring CRRT. The main questions it aims to answer is:\n\n• Does High protein intake (1.5-1.7 g\u002Fkg\u002Fd) reduce the change in RF-CSA, as measured by ultrasonography at day 7 in critically ill patients with AKI requiring CRRT Researchers will compare drug high protein intake to standard protein intake to see if high protein intake effect on muscle mass by ultrasonography.\n\nParticipants will:\n\n* Receive high protein group (1.5-1.7 g\u002Fkg\u002Fd) in High protein group and standard protein intake (1.0-1.2 g\u002Fkg\u002Fd) in control group for 7 days\n* Rectus femoris ultrasonography was performed twice on day 1 and day 7",[89,29],"Acute Kidney Failure Stage 3","2026-05-12",{"date":92,"type":38},"2026-05-19",{"date":69,"type":21},{"date":95,"type":21},"2027-06-30",{"name":97,"class":45},"Chulalongkorn University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":117,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100619553","fluid-balance-guided-by-modified-venous-excess-ultrasonography-versus-standard-care-in-patients-with-acute-kidney-injury-receiving-continuous-renal-replacement-therapy-100619553","NCT07346118","Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy","Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy: A Multicentre Randomised Controlled Trial","mVExUS-CRRT","Inclusion Criteria:\n\n* Adults (≥ 18 years of age)\n* Admitted to ICU\n* Acute kidney injury by KDIGO criteria\n* Initiated CRRT by at least one of the following indications for RRT initiation:\n* Serum potassium ≥ 6.0 mmol\u002FL, or\n* pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol\u002FL, or\n* Evidence of severe respiratory failure, based on a PaO2\u002FFiO2 ≤ 200 and clinical perception of volume overload, or\n* Persistent severe AKI (sCr remains \\> 50% the value recorded at randomization) for \\> 72 hours from randomization\n* Participants giving informed consent\n\nExclusion Criteria:\n\n* Refuse to participate\n* Previous diagnosis of end-stage kidney disease (ESKD) currently on kidney replacement therapy\n* Kidney transplant recipient\n* Receive RRT before ICU admission within 90 days\n* Structural kidney diseases which will interfere with intrarenal doppler ultrasound e.g. renal artery stenosis, autosomal dominant polycystic kidney disease\n* Patients with previously known conditions that interfere with portal doppler assessment, namely liver cirrhosis, severe tricuspid regurgitation with structural heart disease or massive ascites.\n* Underlying disease process with a life expectancy less than 90 days\n* Pregnancy\n* Severe cardiac rhythm disturbances (tachyarrhythmia, supraventricular tachycardia)\n* Intra-cardiac shunts; Ventricle septal defect, patent foramen ovale, atrial septal defect\n* Aortic aneurysm\n* Intra-abdominal hypertension (intraabdominal pressure ≥20 mmHg)\n* Expected life expectancy \\\u003C48 hours\n* Receiving extracorporeal membrane oxygenation (ECMO)",{"count":107,"type":21},126,[86],"The goal of this randomised controlled trial is to compare the cumulative fluid balance over the first 72 h following inclusion guided by mVExUS versus standard of care in critically ill patients with acute kidney injury receiving CRKT . It will also compare the proportion of CRRT-related complications-including intradialytic hypotension and arrhythmias-between patients managed with mVExUS-guided fluid management and those receiving standard care.\n\nThe main questions it aims to answer are:\n\nDoes fluid removal rate guided by mVExUS will reduce cumulative fluid balance over the course of the first 72 h of CRRT in ICU patients compared to standard care\n\nParticipants will:\n\nGet fluid assessment by mVExUS protocol or a strandard care every 8 hours for 72 hours",[111,112,113,29,114,115,116],"AKI - Acute Kidney Injury","Fluid Balance","Acute Circulatory Failure","VExUS","Passive Leg Raising","Biomarkers \u002F Blood",[118,119,120,121,122,123,124,125],"Acute kidney injury","Fluid balance","Acute circulatory failure","Continuous kidney replacement therapy","mVExUS","Modified Venous Excess Ultrasound","Passive leg raising","Biomarker","2026-05-05",{"date":128,"type":38},"2026-05-07",{"date":69,"type":21},{"date":131,"type":21},"2029-05-01",{"name":97,"class":45},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":158},"100469954","phase-3-safety-evaluation-of-prismocitrate-18-in-patients-receiving-crrt-100469954","NCT05399537","Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT","A Safety Evaluation of Prismocitrate 18 in Patients Receiving Continuous Renal Replacement Therapy (CRRT)","Inclusion Criteria:\n\n* Patients must be ≥18 years of age\n* Patients who are candidates for CRRT\n* Patients expected to survive for at least 24 hours\n* Patients with a contraindication to heparin or an increased risk of hemorrhage\n* Patient and\u002For legally-authorized representative has signed a written informed consent form (ICF) per 21 CFR Part 50.55(e)\n\nExclusion Criteria:\n\n* Patients with a known allergy to citrate or who have ever experienced an adverse reaction associated with citrate products, including patients with a prior history of citrate toxicity\n* Patients with acute liver failure, defined by the occurrence of encephalopathy and hepatic synthetic dysfunction within 26 weeks of the first symptoms of liver disease and without evidence of chronic liver disease\n* Patients with acute-on-chronic liver failure characterized by acute decompensation of cirrhosis and a Child-Pugh Liver Failure Score \\>10\n* Patients with refractory shock and associated lactic acidosis (lactate \\>4 mmol\u002FL)\n* Patients with a systemic ionized calcium concentration outside the normal physiologic range (1.0 - 1.3 mmol\u002FL), or outside of the laboratory reference range (Note: It is acceptable to provide calcium supplementation or treatment for hypercalcemia to achieve a normal physiologic range prior to therapy initiation)\n* Female patients of childbearing potential who are pregnant or breastfeeding. (Note: All female patients, who have not undergone a hysterectomy, bilateral oophorectomy with or without hysterectomy, or has medically documented ovarian failure before study Screening must have a negative serum beta human chorionic gonadotropic \\[B-hCG\\] pregnancy test at Screening)\n* Patients who are currently participating in another interventional clinical study",{"count":141,"type":21},40,[143],"PHASE3","Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit. The delivery of CRRT therapy is provided by the PrisMax System which includes regional citrate anticoagulation (RCA) software to facilitate citrate and calcium compensation prescription.\n\nThe objectives of this study are: 1) to confirm the safety of Prismocitrate 18 in patients receiving CRRT using continuous venovenous hemodiafiltration (CVVHDF) or continuous venovenous hemofiltration (CVVH) and 2) to observe that the software and interface for the PrisMax System Version 3.x with calcium line accessory allows for implementation of regional citrate anticoagulation (RCA) (citrate and calcium dosing) during CRRT with Prismocitrate 18 and intended prescription.\n\nThe study period of the patient's CRRT will be up to 10 days.",[146,29,32],"Regional Citrate Anticoagulation (RCA)","RECRUITING","2026-04-10",{"date":150,"type":38},"2026-04-13",{"date":152,"type":38},"2024-07-12",{"date":154,"type":21},"2026-12",{"name":156,"class":157},"Vantive Health LLC","INDUSTRY",14,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":182,"locationsCount":74},"100629009","phase-2-comparison-of-anticoagulant-effects-of-different-doses-of-nafamostat-in-continuous-renal-replacement-therapy-crrt-in-the-intensive-care-unit-icu-100629009","NCT07469072","Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU)","Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU): A Single-Center, Randomized, Open-Label, Parallel-Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age \\& Gender: Aged 18 to 80 years, regardless of gender.\n2. Clinical Indication: Admitted to the Intensive Care Unit (ICU) with a confirmed indication for Continuous Renal Replacement Therapy (CRRT) and an expected treatment duration of greater than 24 hours.\n3. Coagulation Status: Normal coagulation function prior to CRRT initiation, defined as:International Normalized Ratio (INR) ≤ 1.5,Fibrinogen (FIB) ≥ 1.5 g\u002FL,Activated Partial Thromboplastin Time (APTT) ≤ 45 seconds\n4. Platelet Count: Platelet count (PLT) ≥ 50 × 10⁹\u002FL.\n5. Body Mass Index (BMI): 18.5 kg\u002Fm² ≤ BMI ≤ 25 kg\u002Fm².\n6. Informed Consent: Written informed consent obtained from the patient or their legally authorized representative.\n\nExclusion Criteria:\n\n1. Hypersensitivity: Known allergy or hypersensitivity to Nafamostat Mesilate or any component of the formulation.\n2. Active Bleeding: Presence of active bleeding or a high risk of bleeding that contraindicates anticoagulation (e.g., active gastrointestinal bleeding, intracranial hemorrhage, or recent major surgery with a high bleeding risk).\n3. Pregnancy\u002FLactation: Pregnant or breastfeeding women.\n4. Concurrent Anticoagulation: Current use of other systemic anticoagulants (e.g., unfractionated heparin, low molecular weight heparin, warfarin, or direct oral anticoagulants) that cannot be discontinued.\n5. Concurrent Extracorporeal Support: Concurrent use of other extracorporeal life support or blood purification therapies that may interfere with coagulation assessment, such as Extracorporeal Membrane Oxygenation (ECMO), Intra-Aortic Balloon Pump (IABP), or Plasma Exchange (PE).\n6. Severe Liver Dysfunction: Severe hepatic impairment (Child-Pugh Class C) or baseline total bilirubin levels exceeding 5 times the upper limit of normal.\n7. Limited Life Expectancy: Expected survival time of less than 24 hours due to the progression of underlying disease.\n8. Conflicting Trials: Current participation in another interventional clinical trial that may influence the outcomes of this study.","80 Years",{"count":168,"type":21},92,[170],"PHASE2","This is a single-center, randomized, open-label, parallel-controlled clinical trial designed to investigate the anticoagulation efficacy and safety of different initial doses of Nafamostat Mesilate (NM) in ICU patients undergoing Continuous Renal Replacement Therapy (CRRT). Researchers will screen patients admitted to the Department of Critical Care Medicine at Zhujiang Hospital, Southern Medical University, to identify eligible participants based on inclusion and exclusion criteria. After obtaining informed consent, participants will be randomized into two groups.\n\nOn the basis of standardized CRRT treatment, the Low-Dose Group (Group A) will receive a continuous infusion of Nafamostat Mesilate at an initial dose of 20 mg\u002Fh, while the High-Dose Group (Group B) will receive an initial dose of 50 mg\u002Fh. The drug will be continuously infused pre-filter into the CRRT circuit. Dosage adjustments will be made for both groups to maintain target anticoagulation levels while ensuring that pre-filter safety limits are not exceeded. The primary outcome measure is filter lifespan, along with other secondary outcomes.",[29],[29,174,175],"Anticoagulation Efficacy","Nafamostat Mesilate (NM)","2026-04-09",{"date":178,"type":38},"2026-04-14",{"date":180,"type":38},"2026-04-07",{"date":95,"type":21},{"name":183,"class":45},"Zhujiang Hospital",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":74},"100632512","validation-of-a-regional-citrate-anticoagulation-protocol-in-critically-ill-patients-on-continuous-renal-replacement-therapy-100632512","NCT07514650","Validation of a Regional Citrate Anticoagulation Protocol in Critically Ill Patients on Continuous Renal Replacement Therapy","CRRT","Inclusion Criteria\n\n* Age ≥18 years\n* Admission to the intensive care unit (ICU)\n* Diagnosis of acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT)\n* Use of regional citrate anticoagulation during CRRT Exclusion Criteria\n* Known allergy or intolerance to citrate\n* Contraindications to citrate anticoagulation (e.g., severe liver failure or severe metabolic disorders affecting citrate metabolism)\n* Pregnancy or breastfeeding",{"count":192,"type":21},43,[86],"The objective of this study is to evaluate the effectiveness of a modified continuous renal replacement therapy (CRRT) protocol in maintaining electrolyte balance in adult patients with acute kidney injury (AKI) admitted to the intensive care unit (ICU).\n\nThe study assesses whether the use of continuous venovenous hemodiafiltration (CVVHDF) with post-filter replacement under citrate anticoagulation reduces electrolyte losses and the need for electrolyte supplementation compared with standard dialytic CRRT.\n\nParticipants receiving standard CRRT will be compared with those treated with the modified protocol.\n\nThe duration of participation corresponds to the period during which CRRT is required. Data collection will cease once CRRT is discontinued.",[28,196,29,197],"ICU Patients","Electrolytes",[199,28,200,201,202,197],"Regional Citrate Anticoagulation","ICU patients","Continuous Renal Replacement Therapy","Diluted citrate","2026-04-01",{"date":180,"type":38},{"date":206,"type":38},"2024-11-24",{"date":208,"type":21},"2026-11",{"name":210,"class":45},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":189,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":218,"targetDuration":220,"studyType":57,"phases":4,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":74},"100627322","prospective-analysis-of-arteriovenous-access-ava-use-for-continuous-renal-replacement-therapy-crrt-100627322","NCT07447128","Prospective Analysis of Arteriovenous Access (AVA) Use for Continuous Renal Replacement Therapy (CRRT)","Prospective Analysis of Arteriovenous Access Use in Continuous Renal Replacement Therapy, a Feasibility Project","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of End-Stage Kidney Disease (ESKD) receiving maintenance chronic hemodialysis\n* Admission to the Intensive Care Unit (ICU)\n* Presence of a functioning arteriovenous fistula (AVF) or arteriovenous graft (AVG)\n* Clinical indication for Continuous Renal Replacement Therapy (CRRT)\n* Score of ≥16 points on the study enrollment screening tool\n\nExclusion Criteria:\n\n* Age under 18 years\n* Arteriovenous access thrombectomy within 30 days prior to study enrollment\n* Documented prolonged bleeding from arteriovenous access within 30 days prior to study enrollment\n* Current dialysis via temporary or tunneled hemodialysis catheter\n* International Normalized Ratio (INR) \\> 3.0\n* Acute liver failure, defined as AST \\> 1000 U\u002FL and\u002For ALT \\> 1000 U\u002FL\n* Platelet count \\\u003C 50,000\u002FµL\n* Evidence of disseminated intravascular coagulation (DIC)\n* Pregnant patients\n* Patients actively attempting to become pregnant",{"count":219,"type":21},50,"30 Days","Arteriovenous fistula or graft are the ideal hemodialysis access. Nonetheless the most common access type used for Continuous Renal Replacement Therapy (CRRT) is either a temporary or permanent hemodialysis catheter. Recommendations for the use of catheters to deliver CRRT in end stage kidney disease (ESKD) patients are lacking on data and subjective to anecdotal experiences and expert consensus. The repetitive placement of catheters in ESKD patients have shown to increase the chances of central vascular stenosis which is one of the main risk factors that lead to access failure. Also, the repetitive use of dialysis catheters increases the risk for catheter associated infections. Dedicated studies demonstrating the safety and feasibility of using arteriovenous access (AVA) for CRRT are scarce. No screening criteria or algorithm exists to determine the adequate patient and clinical scenario to use AVA for CRRT.\n\nGoals of the study:\n\n1. To develop a standard operating procedure for the use of AVA in CRRT.\n2. Evaluate the safety and efficacy of using AVA for CRRT.",[29,223],"End Stage Kidney Disease (ESRD)",[225,201,189,226,227,228],"Arteriovenous access","AVA","ESKD","End Stage Kidney Disease","2026-02-27",{"date":231,"type":38},"2026-03-03",{"date":233,"type":21},"2026-03",{"date":235,"type":21},"2026-09",{"name":237,"class":45},"East Carolina University",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":22,"phases":247,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":4},"100585334","continuous-renal-replacement-therapy-doses-in-critically-ill-patients-with-acute-kidney-injury-100585334","NCT06901011","Continuous Renal Replacement Therapy Doses in Critically Ill Patients With Acute Kidney Injury","CRRIT1","Inclusion Criteria:\n\n* Patients 18 years of age or older\n* Acute renal failure (AKIN 3) requiring Continuous Renal Replacement Therapy\n* Requirement of vasoactive drugs (norepinephrine \\> 0.1 mcg\u002Fkg\u002Fmin)\n* Written informed consent (patient or family)\n\nExclusion Criteria:\n\n* Lack of informed consent.\n* Possibility of using plasma exchange or MARS therapy at the at the time of inclusion.\n* Baseline renal function with an estimated glomerular filtration rate (CKD-EPI) less than 30 ml\u002Fmin.",{"count":246,"type":21},100,[86],"Acute kidney injury in critically ill patients admitted to the ICU is a common complication associated with high mortality or long-term chronic kidney damage. Some of these patients require continuous renal replacement therapy (low-intensity hemodialysis for 24 hours) until renal function recovery is achieved.\n\nContinuous Renal Replacement Therapy (CRRT) is a crucial treatment for ICU patients with acute renal failure. It offers continuous toxin removal and prevents fluid accumulation in the patient's body. The therapy not only eliminates toxins but also physiological substances, including micronutrients and essential elements for cellular metabolism and organ function.\n\nCurrently, there is limited information available to adjust the renal therapy dose and avoid or balance the loss of these substances without causing toxin accumulation. Some studies suggest that high doses of therapy do not provide benefits and increase complications.\n\nThe objective of this study is to evaluate two doses of continuous renal therapy in terms of internal environment control (sodium, potassium, and acids and bases), micronutrient loss, and toxin elimination. After 48 hours of therapy, patients will be assigned to continue with a dose equal to the initial dose or a decrease in the initial dose. These two options are part of the current standard practice in our center.\n\nPatients participating in the study will be randomly assigned one of the continuous renal therapy doses. The study is open, so treating physicians will always know the therapy the patient is receiving and can freely adjust it if deemed necessary.\n\nThe intervention duration is 96 hours, after which the dose will be at the discretion of the treating medical team. A follow-up will be conducted through medical records or phone calls approximately 90 days after starting therapy.\n\nThe risks for the patient are minimal, as toxin elimination monitoring will be even more intensive than usual. The study plans to include approximately 100 patients.",[250,29],"Renal Replacement Therapy for Acute Kidney Injury in ICU",[29,250,252],"dialytrauma","2025-07-14",{"date":255,"type":38},"2025-07-17",{"date":257,"type":21},"2025-08-01",{"date":259,"type":21},"2027-08",{"name":261,"class":45},"Fundacion Clinic per a la Recerca Biomédica",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":276,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":4},"100593368","ultrasound-guided-microbubble-removal-and-filter-lifespan-during-crrt-a-pilot-crossover-study-100593368","NCT07005531","Ultrasound-Guided Microbubble Removal and Filter Lifespan During CRRT: A Pilot Crossover Study","Impact of Ultrasound-Guided Microbubble Clearance During CRRT Circuit Priming on Filter Lifespan: A Randomized Crossover Pilot Trial","Inclusion Criteria:\n\n* Age ≥18 years, regardless of sex;\n* Admission to the intensive care unit (ICU) with a diagnosis of acute kidney injury (AKI) or chronic kidney disease (CKD) requiring continuous renal replacement therapy (CRRT);\n* Expected to receive at least two sessions of CRRT;\n* Written informed consent obtained from the patient or their legally authorized representative.\n\nExclusion Criteria:\n\n* Presence of severe coagulopathy (such as disseminated intravascular coagulation, DIC) or platelet count \\\u003C30×10\\^9\u002FL;\n* Contraindications to anticoagulation therapy;\n* Change in APACHE II score \\>5 points, or changes in coagulation parameters and platelet count exceeding 20% between the two treatment sessions;\n* Any other condition deemed unsuitable for participation by the investigators.",{"count":141,"type":21},[86],"What is this study about? This study is designed to evaluate whether ultrasound-guided removal of microbubbles during circuit priming in Continuous Renal Replacement Therapy (CRRT) can extend the filter lifespan for critically ill patients who require CRRT. The investigators aim to determine if this technique improves the duration of effective filter use and reduces complications related to filter clotting.\n\nWho can join? Adults (18 years or older) admitted to the Intensive Care Unit (ICU) and diagnosed with acute kidney injury (AKI) or chronic kidney failure (CKD) who require CRRT and are expected to undergo at least two sessions of CRRT treatment.\n\nParticipants or their legal representatives must provide signed informed consent.\n\nWho cannot join? Patients with severe coagulation disorders, platelet count \\\u003C30×10\\^9\u002FL, contraindications to anticoagulation, significant changes in clinical scores or blood tests between CRRT sessions, or any other condition deemed unsuitable by the investigator.\n\nWhat will happen during the study?\n\nTwo Treatment Methods:\n\nConventional Priming (Control): The CRRT circuit will be primed following the standard visual bubble inspection protocol.\n\nUltrasound-Guided Priming (Intervention): The circuit will be primed using real-time ultrasound to detect and remove microbubbles from key locations.\n\nEach participant will receive both interventions in random order, separated by a washout period of at least 24 hours.\n\nSafe and Routine Monitoring:\n\nUltrasound scans will be performed on the filter and circuit to guide microbubble removal.\n\nStandardized CRRT treatment protocols, including filter type and anticoagulation regimen, will be used for all sessions.\n\nOther Data Collection:\n\nPatient information (e.g., age, sex, medical history, APACHE II score) CRRT treatment details (e.g., filter lifespan, filter clotting incidence, coagulation parameters) Monitoring of adverse events and clinical outcomes (including 28-day survival and treatment costs) What are the benefits and risks? Benefits: This study may provide evidence for a simple, non-invasive method to reduce filter clotting, improve CRRT efficiency, and enhance patient outcomes.\n\nRisks: Ultrasound monitoring is non-invasive and does not add risk beyond standard care. All procedures are standard clinical practice.\n\nYour Rights and Safety Voluntary Participation: Participation is voluntary; withdrawal is allowed at any time without affecting clinical care.\n\nEthical Approval: The study protocol is reviewed and approved by the hospital's ethics committee.\n\nConfidentiality: All personal information and test results will be kept confidential.",[28,29,273,274,275],"Filter Clotting","Microbubbles","Ultrasound-Guided Microbubble Removal",[29,277,274,278,273,279,280,281],"Filter Lifespan","Ultrasound Guidance","Circuit Priming","Critical Care","Randomized Crossover Trial","2025-06-03",{"date":284,"type":38},"2025-06-05",{"date":286,"type":21},"2025-06-30",{"date":288,"type":21},"2026-06-29",{"name":290,"class":45},"First Affiliated Hospital of Wannan Medical College"]